Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activ

PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke

(2018) Ranjeet K. Sinha et al.   BLOOD

Using the National Institutes of Health Stroke Scale

(2017) Patrick Lyden   STROKE

2016 Scientific Sessions Sol Sherry Distinguished Lecturer in ThrombosisHighlights

(2016) John H. Griffin et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

3K3A–activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice

(2016) Yaoming Wang et al.   NATURE MEDICINE

Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection

(2016) Patrick Lyden et al.   STROKE

Activated protein C promotes neuroprotection: mechanisms and translation to the clinic

(2016) John H. Griffin et al.   THROMBOSIS RESEARCH

Activated protein C: biased for translation

(2015) J. H. Griffin et al.   BLOOD

Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke

(2015) Mayank Goyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection

(2015) Bruce C.V. Campbell et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke

(2015) Olvert A. Berkhemer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers

(2014) Patrick Lyden et al.   CURRENT PHARMACEUTICAL DESIGN

An Activated Protein C Analog Stimulates Neuronal Production by Human Neural Progenitor Cells via a PAR1-PAR3-S1PR1-Akt Pathway

(2013) H. Guo et al.   JOURNAL OF NEUROSCIENCE

Activated Protein C Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats

(2013) Yaoming Wang et al.   STROKE

Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46

(2012) L. O. Mosnier et al.   BLOOD

Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke

(2012) Patricia D. Williams et al.   CURRENT PHARMACEUTICAL DESIGN

An Activated Protein C Analog With Reduced Anticoagulant Activity Extends the Therapeutic Window of Tissue Plasminogen Activator for Ischemic Stroke in Rodents

(2012) Yaoming Wang et al.   STROKE

Cytoprotective protein C pathways and implications for stroke and neurological disorders

(2011) Berislav V. Zlokovic et al.   TRENDS IN NEUROSCIENCES

Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact

(2010) Corey T. Walker et al.   BRAIN RESEARCH

Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity

(2009) Huang Guo et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity

(2009) Huang Guo et al.   JOURNAL OF NEUROCHEMISTRY

Cerebral microbleeds: a guide to detection and interpretation

(2009) Steven M Greenberg et al.   LANCET NEUROLOGY

Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations

(2009) Marc Fisher et al.   STROKE

Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets

(2008) May H. Han et al.   NATURE

Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke

(2008) Werner Hacke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential Neuroprotection and Risk for Bleeding From Activated Protein C With Varying Degrees of Anticoagulant Activity

(2008) Yaoming Wang et al.   STROKE